Study finds slight improvement in reporting adverse effects in drug trials over the last 17 years
Researchers, including academics from the University of York, analyzed systematic reviews of 1,200 Randomized Controlled Trials (RCTs) to assess whether reporting had improved over time.
However, the information the researchers needed to assess what adverse effects were reported (and how they were reported) was only included in less than half of the RCTs they analysed.
Drug trials are conducted to give clinicians information on the benefits and adverse effects of treatments. Our study shows that, disappointingly, there s only been a slight improvement in reporting the adverse effects in trials over the last 17 years.
AI Recognizes a Pattern in Biopsies from Blistering Disease azorobotics.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from azorobotics.com Daily Mail and Mail on Sunday newspapers.
Scientists study how our immune system responds to COVID-19 variants
Australian scientists researching how our immune system responds to COVID-19 have revealed that those infected by early variants in 2020 produced sustained antibodies, however, these antibodies are not as effective against contemporary variants of the virus.
The research is one of the world s most comprehensive studies of the immune response against COVID-19 infection. It suggests vaccination is more effective than the body s natural immune response following infection and shows the need to invest in new vaccine designs to keep pace with emerging COVID variants.
Published today in
PLOS Medicine, the study was made possible by a partnership between the University of Sydney, Kids Research, Sydney Children s Hospitals Network, the Kirby Institute at UNSW Sydney, Australian Red Cross Lifeblood, St Vincent s Hospital and NSW Health Pathology, as well as other local and international collaborators.
Study uncovers the complex cellular mechanisms of Ebola virus
Mount Sinai researchers have uncovered the complex cellular mechanisms of the Ebola virus, which could help explain its severe toll on humans and identify potential pathways to treatment and prevention. In a study published in
mBio, the team reported how a protein of the Ebola virus, VP24, interacts with the double-layered membrane of the cell nucleus (known as the nuclear envelope), leading to significant damage to cells along with virus replication and the propagation of disease.
The Ebola virus is extremely skilled at dodging the body s immune defenses, and in our study, we characterize an important way in which that evasion occurs through disruption of the nuclear envelope, mediated by the VP24 protein. That disruption is quite dramatic and replicates rare, genetic diseases known as laminopathies, which can result in severe muscular, cardiovascular, and neuronal complications.
Inventor gender gap partially responsible for many missing female-focused inventions
Jul 7 2021
Necessity is the father of invention, but where is its mother? According to a new study published in
Science, fewer women hold biomedical patents, leading to a reduced number of patented technologies designed to address problems affecting women.
While there are well-known biases that limit the number of women in science and technology, the consequences extend beyond the gender gap in the labour market, say researchers from McGill University, Harvard Business School, and the Universidad de Navarra in Barcelona. Demographic inequities in who gets to invent lead to demographic inequities in who benefits from invention.